Needham analyst Ami Fadia maintained a Buy rating on Jazz Pharmaceuticals (NASDAQ:JAZZ) on Friday, setting a price target of $215, which is approximately 72.65% above the present share price of $124.53.
Fadia expects Jazz Pharmaceuticals to post earnings per share (EPS) of -$0.86 for the fourth quarter of 2021.
The current consensus among 12 TipRanks analysts is for a Strong Buy rating of shares in Jazz Pharmaceuticals, with an average price target of $201.25.
The analysts price targets range from a high of $230 to a low of $172.
In its latest earnings report, released on 09/30/2021, the company reported a quarterly revenue of $838.12 million and a net profit of $28.37 million. The company's market cap is $7.65 billion.
According to TipRanks.com, Needham analyst Ami Fadia is currently ranked with 1 stars on a 0-5 stars ranking scale, with an average return of -3.3% and a 37.29% success rate.
Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: XYREM, ERWINAZETM, PRIALT, intrathecal infusion, FAZACLO and LUVOX CR. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.